AU2014229468A1 - Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer - Google Patents

Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer Download PDF

Info

Publication number
AU2014229468A1
AU2014229468A1 AU2014229468A AU2014229468A AU2014229468A1 AU 2014229468 A1 AU2014229468 A1 AU 2014229468A1 AU 2014229468 A AU2014229468 A AU 2014229468A AU 2014229468 A AU2014229468 A AU 2014229468A AU 2014229468 A1 AU2014229468 A1 AU 2014229468A1
Authority
AU
Australia
Prior art keywords
egfr
inhibitor
compound
dacomitinib
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014229468A
Other languages
English (en)
Inventor
Zelanna Iris GOLDBERG
John Charles Kath
Stephen Paul Letrent
Scott Lawrence Weinrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2014229468A1 publication Critical patent/AU2014229468A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014229468A 2013-03-14 2014-03-03 Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer Abandoned AU2014229468A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786130P 2013-03-14 2013-03-14
US61/786,130 2013-03-14
PCT/IB2014/059401 WO2014140989A2 (en) 2013-03-14 2014-03-03 Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
AU2014229468A1 true AU2014229468A1 (en) 2015-09-03

Family

ID=50288209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014229468A Abandoned AU2014229468A1 (en) 2013-03-14 2014-03-03 Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer

Country Status (14)

Country Link
EP (1) EP2968336A2 (zh)
JP (1) JP2014177456A (zh)
KR (1) KR20150119210A (zh)
CN (1) CN105073116A (zh)
AR (1) AR095197A1 (zh)
AU (1) AU2014229468A1 (zh)
BR (1) BR112015023020A2 (zh)
CA (1) CA2904797A1 (zh)
IL (1) IL240730A0 (zh)
MX (1) MX2015012106A (zh)
RU (1) RU2015137596A (zh)
SG (1) SG11201506531WA (zh)
TW (1) TW201446248A (zh)
WO (1) WO2014140989A2 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140059246A (ko) 2011-09-22 2014-05-15 화이자 인코포레이티드 피롤로피리미딘 및 퓨린 유도체
WO2015039612A1 (zh) 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
WO2016051380A1 (en) * 2014-10-01 2016-04-07 Sun Pharmaceutical Industries Limited Crystalline form of afatinib dimaleate
US10507210B2 (en) 2014-12-03 2019-12-17 Auckland Uniservices Limited Kinase inhibitor prodrug for the treatment of cancer
US10538518B2 (en) * 2015-08-11 2020-01-21 Principia Biopharma, Inc. Processes for preparing an FGFR inhibitor
WO2017164887A1 (en) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods for treatment
US10583142B2 (en) 2016-03-25 2020-03-10 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods of treatment
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
US10813933B2 (en) 2016-05-17 2020-10-27 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
WO2017198602A1 (en) * 2016-05-18 2017-11-23 Boehringer Ingelheim International Gmbh Anticancer combination therapy
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
JP2020510027A (ja) * 2017-03-08 2020-04-02 アリアド ファーマシューティカルズ，インコーポレーテッド ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンを含む医薬製剤
EA202091372A1 (ru) 2017-12-05 2020-10-05 Оскотек Инк. Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2
WO2024026056A2 (en) * 2022-07-29 2024-02-01 Accutar Biotechnology, Inc. Heteroaryl compounds as egfr inhibitors and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
KR20140059246A (ko) * 2011-09-22 2014-05-15 화이자 인코포레이티드 피롤로피리미딘 및 퓨린 유도체

Also Published As

Publication number Publication date
AR095197A1 (es) 2015-09-30
RU2015137596A (ru) 2017-04-17
JP2014177456A (ja) 2014-09-25
CA2904797A1 (en) 2014-09-18
SG11201506531WA (en) 2015-09-29
WO2014140989A3 (en) 2014-12-04
BR112015023020A2 (pt) 2017-07-18
KR20150119210A (ko) 2015-10-23
TW201446248A (zh) 2014-12-16
EP2968336A2 (en) 2016-01-20
MX2015012106A (es) 2016-01-12
CN105073116A (zh) 2015-11-18
WO2014140989A2 (en) 2014-09-18
IL240730A0 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
AU2014229468A1 (en) Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer
US20200325130A1 (en) Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same
CA3158254C (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
US10258603B2 (en) Therapeutic compounds and uses thereof
JP2022106953A (ja) ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体
JP2018141005A (ja) 新規なアミノピリミジン誘導体
AU2017286654A1 (en) Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
KR20190038915A (ko) 피리도피리미딘온 cdk2/4/6 억제제
EP3455219A1 (en) Amine-linked c3-glutarimide degronimers for target protein degradation
KR20200108298A (ko) 벤즈아미드 화합물
KR20210044822A (ko) 피롤로피리미딘 itk 억제제
JP2012511502A (ja) ジヒドロピリミドピリミジン誘導体
US20130096149A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors
BR112020013247A2 (pt) amidas heterocíclicas como inibidores de quinase
JP2023502662A (ja) Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
JP2022531088A (ja) Ｊａｋ阻害剤としての置換ピロロピリジン
CA3145864A1 (en) Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
US20230057166A1 (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
KR20220034038A (ko) Bcl-2 억제제의 나노입자 제형
WO2024020084A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
EP2476682A1 (en) 8-oxodihydropurine derivative
WO2019145719A1 (en) Inhibitors of ras-effector protein interactions
WO2024076672A1 (en) Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
WO2022170164A1 (en) Sulfonamides with egfr inhibition activities and their use thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period